Patents by Inventor Sylwia Stachura

Sylwia Stachura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
    Patent number: 10479793
    Abstract: Compounds of formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: November 19, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: David S. Weinstein, Ryan M. Moslin, Yanlei Zhang, Daniel S. Gardner, Joseph B. Santella, Charles M. Langevine, Sylwia Stachura
  • IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20180325899
    Abstract: Compounds of formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: November 17, 2016
    Publication date: November 15, 2018
    Inventors: David S. Weinstein, Ryan M. Moslin, Yanlei Zhang, Daniel S. Gardner, Joseph B. Santella, Charles M. Langevine, Sylwia Stachura
  • OXAZOLOBENZIMIDAZOLE DERIVATIVES
    Publication number: 20110178117
    Abstract: The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Application
    Filed: September 16, 2009
    Publication date: July 21, 2011
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Antonella Converso, Timothy John Hartingh, Sylwia Stachura